Information Provided By: 
Fly News Breaks for September 19, 2017
DMTX, RARE
Sep 19, 2017 | 08:44 EDT
Wedbush analyst David Nierengarten says that a successful acquisition of Dimension Therapeutics (DMTX) would mark Ultragenyx's (RARE) entry into the gene therapy space, and would be a natural extension of the latter's rare disease focus. The analyst expects the bid to go through. Nierengarten reiterates an Outperform rating and $62 price target on Ultragenyx shares.
News For RARE;DMTX From the Last 2 Days
